Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $20 at JPMorgan
Tweet
Share
E-mailGet Alerts BHVN Hot Sheet
Price: $10.81 +6.71%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
JPMorgan analyst Tessa Romero lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $20.00 (from $23.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
- MaxLinear (MXL) PT Raised to $105 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
